Demographics of study population (n=22)
| Characteristic . | Quantity . |
|---|---|
| Newly diagnosed, no. (%) | 14 (64) |
| Late CP, no. (%) | 8 (36) |
| Age, y (range) | 49 (25-57) |
| Prior imatinib therapy, no. (%) | 11 (50) |
| Response to imatinib prior to SCT, no. (%) | |
| CCR | 4 (18) |
| MCR | 1 (5) |
| Less than MCR | 5* (23) |
| Loss of CCR | 1† (5) |
| Indications for allograft, no.(%) | |
| Patient choice | 16 (73) |
| Suboptimal response to imatinib | 6 (27) |
| Disease status at time of transplantation, no. (%) | |
| CCR | 4 (18) |
| Less than CCR | 18 (82) |
| CD34+ cells/kg, ×106 (range) | 6.4 (2.79-13.9) |
| Engraftment, d (range) | |
| Neutrophils over 0.5 × 109/L | 19 (11-38) |
| Platelets over 50 × 109/L | 19 (11-44) |
| GVHD after SCT, no. (%) | |
| Acute | 1 (5) |
| Chronic | 0 (0) |
| GVHD after DLI, no. (%) | |
| Acute | 4 (31) |
| Chronic | 1 (8) |
| TRM, no. (%) | |
| At 100 d | 0 (0) |
| At 12 mo | 1 (5) |
| After DLI | 2 (9) |
| Characteristic . | Quantity . |
|---|---|
| Newly diagnosed, no. (%) | 14 (64) |
| Late CP, no. (%) | 8 (36) |
| Age, y (range) | 49 (25-57) |
| Prior imatinib therapy, no. (%) | 11 (50) |
| Response to imatinib prior to SCT, no. (%) | |
| CCR | 4 (18) |
| MCR | 1 (5) |
| Less than MCR | 5* (23) |
| Loss of CCR | 1† (5) |
| Indications for allograft, no.(%) | |
| Patient choice | 16 (73) |
| Suboptimal response to imatinib | 6 (27) |
| Disease status at time of transplantation, no. (%) | |
| CCR | 4 (18) |
| Less than CCR | 18 (82) |
| CD34+ cells/kg, ×106 (range) | 6.4 (2.79-13.9) |
| Engraftment, d (range) | |
| Neutrophils over 0.5 × 109/L | 19 (11-38) |
| Platelets over 50 × 109/L | 19 (11-44) |
| GVHD after SCT, no. (%) | |
| Acute | 1 (5) |
| Chronic | 0 (0) |
| GVHD after DLI, no. (%) | |
| Acute | 4 (31) |
| Chronic | 1 (8) |
| TRM, no. (%) | |
| At 100 d | 0 (0) |
| At 12 mo | 1 (5) |
| After DLI | 2 (9) |
Late CP is defined as greater than 12 months from diagnosis; CCR, complete cytogenetic remission defined as no detectable Ph+ metaphases in the bone marrow; and MCR, major cytogenetic remission defined as 1% to 35% Ph+ metaphases in the bone marrow.
No ABL kinase domain mutation detected.
ABL kinase domain mutation detected.